Physician profile
Holly Hare Mccoppin
NPI 1003011404
$8,411.17
in general payments reported to CMS, 2019-2025
34 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $862 · 2021: $1,219 · 2022: $1,267 · 2023: $1,364 · 2024: $1,670 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,249 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,249.33 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,761.75 | 2019-2025 | |
| Genzyme Corporation | $943.18 | 2019-2025 | |
| Lilly USA, LLC | $882.59 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $852.82 | 2019-2025 | Blu-U, Odomzo, Ilumya |
| Novartis Pharmaceuticals Corporation | $506.98 | 2019-2025 | |
| Janssen Biotech, INC. | $423.15 | 2019-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $414.63 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $331.74 | 2021-2025 | Bimzelx |
| Leo Pharma INC. | $302.39 | 2021-2025 | Adbry |
| Galderma Laboratories, L.P. | $296.13 | 2019-2025 | Nemluvio |
| Pfizer INC. | $291.03 | 2019-2025 | |
| Amgen INC. | $239.32 | 2020-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $182.68 | 2022-2025 | Sotyktu |
| Incyte Corporation | $132.54 | 2021-2024 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $118.06 | 2019-2025 | Siliq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $98.31 | 2019-2025 | Klisyri |
| Organon LLC | $87.01 | 2025 | Hadlima |
| Dermira, INC. | $63.52 | 2020-2021 | |
| Biocon Biologics INC | $54.56 | 2023-2024 | Hulio |
| Dermavant Sciences, INC. | $54.04 | 2023-2024 | Vtama |
| Convatec INC. | $43.87 | 2025 | |
| Acera Surgical, INC. | $41.29 | 2021-2022 | |
| Biofrontera INC. | $40.86 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $37.28 | 2020-2021 | |
| Verrica Pharmaceuticals INC. | $35.99 | 2023 | Ycanth |
| Arcutis Biotherapeutics, INC. | $28.32 | 2023 | |
| Dilon Technologies, INC. | $21.92 | 2024 | Hemoblast Bellows |
| Mylan Institutional INC. | $21.44 | 2023 | |
| Mylan Pharmaceuticals INC. | $21.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.68 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.52 | 2020 | |
| Epi Health, LLC | $15.66 | 2020 | |
| Mayne Pharma Commercial LLC | $14.74 | 2019 | |
| Journey Medical Corporation | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Mccoppin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.